BioCentury | Dec 5, 2020
Product Development

Dec. 4 Quick Takes: Zogenix in Dravet deal with start-up; plus updates from BioCryst, Takeda, AB Science, Sutro, Lilly, Cedars-Sinai

Aiming to reverse Dravet, Tevard partners with ZogenixZogenix Inc. (NASDAQ:ZGNX) will collaborate with Tevard Biosciences to develop transfer RNA-based gene therapies to treat Dravet syndrome and other genetic epilepsies. The Cambridge, Mass.-based start-up, which has...
BioCentury | Jun 17, 2020
Emerging Company Profile

Lightspeed, Klausner back Stanford cell therapy spinout Orca in new $192M round

...Cell Biology and Regenerative Medicine and an Orca Bio co-founder and adviser. The company’s two core technologies...
BioCentury | Jun 16, 2020
Product Development

Bit Bio scales up cell programming ambitions with $41.5M from blue-chip investors

With a $41.5 million series A round led by Rick Klausner, Arch and Foresite, Bit Bio is moving beyond commercializing a handful a cell types to the moonshot goal of generating every cell type in...
BioCentury | Mar 5, 2020
Emerging Company Profile

AiCure: harnessing AI to boost adherence

AiCure is combining a decade’s worth of research into real-world patient behavior with an artificial intelligence platform to optimize patient adherence to treatments in clinical trials. Lack of patient compliance to long-term treatments can lead...
BioCentury | Mar 2, 2020
Finance

Immunocore’s $130M series B gives new CEO Jallal capital to progress pipeline

Nearly five years after Immunocore raised what was then the largest-ever European venture round at $320 million, the company has raised a fresh $130 million from a syndicate featuring seven new investors to both advance...
BioCentury | Feb 20, 2020
Emerging Company Profile

C. Light opens retinal window to neurological disease

UC Berkeley spinout C. Light thinks its retina tracking technology could capture early signs of neurological diseases and variability across different patients. “We’re looking to change neurology from a reactionary area of medicine to a...
BioCentury | Jan 4, 2020
Tools & Techniques

BioNTech tackles solid tumors by pairing CAR Ts with RNA vaccines

...BioNTech is marrying two of its core technologies -- RNA therapeutics and engineered cell therapies -- to...
BioCentury | Dec 11, 2019
Emerging Company Profile

Flagship’s Cellarity maps out network-based drug discovery

Cellarity debuted Tuesday with technology to leverage single cell data to identify compounds that trigger protective changes in molecular networks, without needing to pin their therapeutic effects onto a single target. With $50 million in...
BioCentury | Nov 1, 2019
Tools & Techniques

Draper’s devices take on cell therapy’s pain points

...are so new,” said Balestrini. Draper is responding to those concerns with a toolbox of core technologies...
BioCentury | Sep 18, 2019
Politics & Policy

CFIUS rules mum on foundational tech definition

...Association cautioned against too broad a definition. BIO proposed defining emerging technologies as specific non-mature core technologies...
Items per page:
1 - 10 of 134
BioCentury | Dec 5, 2020
Product Development

Dec. 4 Quick Takes: Zogenix in Dravet deal with start-up; plus updates from BioCryst, Takeda, AB Science, Sutro, Lilly, Cedars-Sinai

Aiming to reverse Dravet, Tevard partners with ZogenixZogenix Inc. (NASDAQ:ZGNX) will collaborate with Tevard Biosciences to develop transfer RNA-based gene therapies to treat Dravet syndrome and other genetic epilepsies. The Cambridge, Mass.-based start-up, which has...
BioCentury | Jun 17, 2020
Emerging Company Profile

Lightspeed, Klausner back Stanford cell therapy spinout Orca in new $192M round

...Cell Biology and Regenerative Medicine and an Orca Bio co-founder and adviser. The company’s two core technologies...
BioCentury | Jun 16, 2020
Product Development

Bit Bio scales up cell programming ambitions with $41.5M from blue-chip investors

With a $41.5 million series A round led by Rick Klausner, Arch and Foresite, Bit Bio is moving beyond commercializing a handful a cell types to the moonshot goal of generating every cell type in...
BioCentury | Mar 5, 2020
Emerging Company Profile

AiCure: harnessing AI to boost adherence

AiCure is combining a decade’s worth of research into real-world patient behavior with an artificial intelligence platform to optimize patient adherence to treatments in clinical trials. Lack of patient compliance to long-term treatments can lead...
BioCentury | Mar 2, 2020
Finance

Immunocore’s $130M series B gives new CEO Jallal capital to progress pipeline

Nearly five years after Immunocore raised what was then the largest-ever European venture round at $320 million, the company has raised a fresh $130 million from a syndicate featuring seven new investors to both advance...
BioCentury | Feb 20, 2020
Emerging Company Profile

C. Light opens retinal window to neurological disease

UC Berkeley spinout C. Light thinks its retina tracking technology could capture early signs of neurological diseases and variability across different patients. “We’re looking to change neurology from a reactionary area of medicine to a...
BioCentury | Jan 4, 2020
Tools & Techniques

BioNTech tackles solid tumors by pairing CAR Ts with RNA vaccines

...BioNTech is marrying two of its core technologies -- RNA therapeutics and engineered cell therapies -- to...
BioCentury | Dec 11, 2019
Emerging Company Profile

Flagship’s Cellarity maps out network-based drug discovery

Cellarity debuted Tuesday with technology to leverage single cell data to identify compounds that trigger protective changes in molecular networks, without needing to pin their therapeutic effects onto a single target. With $50 million in...
BioCentury | Nov 1, 2019
Tools & Techniques

Draper’s devices take on cell therapy’s pain points

...are so new,” said Balestrini. Draper is responding to those concerns with a toolbox of core technologies...
BioCentury | Sep 18, 2019
Politics & Policy

CFIUS rules mum on foundational tech definition

...Association cautioned against too broad a definition. BIO proposed defining emerging technologies as specific non-mature core technologies...
Items per page:
1 - 10 of 134